肿瘤防治研究2019，Vol.46Issue(4)：376-381,6.DOI:10.3971/j.issn.1000-8578.2019.18.1016
靶向HER2阳性肿瘤的PET/CT分子显像临床研究进展
Progress in PET/CT Molecular Imaging Targeting HER2-positive Tumour
周妮娜 1朱华 1杨志1
作者信息
- 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科,恶性肿瘤发病机制及转化研究教育部重点实验室,100142 北京
- 折叠
摘要
Abstract
Human epidermal growth factor receptor 2 (HER2) is expressed in various tumors. Trastuzumab can significantly improve the overall survival time of HER2-positive breast cancer and gastric cancer patients.At present, the detection methods of HER2 overexpression are mainly IHC and FISH. However, this invasive examination can not be used as a routine examination. PET/CT molecular imaging targeting HER2 is expected to monitor the HER2 expression in whole-body lesions in real time and non-invasively. At present, PET/CT molecular imaging targeting HER2 mainly includes nuclide-labeled antibody imaging, nuclidelabeled affibody/antibody fragment/nanoantibody imaging. It can be used to monitor the expression and the heterogeneity of HER2, screen positive metastatic foci in patients with primary HER2-negative breast cancer and predict the curative effect. Long half-life nuclide (～ (64) Cu, 89Zr) labeled intact antibody can directly assess the situation of HER2 binding to trastuzumab, but its blood pharmacokinetics and blood clearance are slow, and long-time imaging is needed. In addition, the long half-life nuclides lead to higher radiation dose. Short half-life nuclide (～ (68) Ga) labeled affibody/antibody fragment/nanoantibody imaging, due to its small molecular weight, fast biological distribution and short-time imaging (1-4h) after the injection of drugs, can increase the convenience of the patients and be repeatedly imaged. As the binding site is different from antibody, affibody can be used for the imaging in target therapy. Also, the radiation caused by short half-life nuclide is significantly lower than that by long half-life nuclides, and may be more suitable for clinical application.关键词
HER2/PET/CT/分子显像/靶向Key words
HER2/PET/CT/Molecular imaging/Targeting分类
医药卫生引用本文复制引用
周妮娜,朱华,杨志..靶向HER2阳性肿瘤的PET/CT分子显像临床研究进展[J].肿瘤防治研究,2019,46(4):376-381,6.
